Prescient Therapeutics opens first clinical site for Phase 2a PTX-100 trial in cutaneous T-cell lymphoma
Prescient Therapeutics Ltd (ASX: PTX) initiates a Phase 2a clinical trial for PTX-100 in cutaneous...
Prescient Therapeutics Ltd (ASX: PTX) initiates a Phase 2a clinical trial for PTX-100 in cutaneous...
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a...
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased...
In the latest announcement, clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) revealed the receipt...
Encouraging outcomes from Prescient Therapeutics’ (ASX: PTX) clinical-stage assets light up last quarter and products...
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal...
Prescient Therapeutics (ASX: PTX) -- a publicly listed oncology company developing targeted and cell therapies...
ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr...
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.